Paul Goss
Overview
Explore the profile of Paul Goss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paulino E, de Melo A, Silva-Filho A, de Freitas Maciel L, Thuler L, Goss P, et al.
JCO Glob Oncol
. 2020 Oct;
6:1617-1630.
PMID: 33108231
Purpose: Little is known, or has been published previously, regarding consolidated data on the epidemiology of gynecologic cancers (GC) in Brazil. This article describes the incidence, morbidity, and mortality of...
2.
Ho V, Pasquet R, Luo S, Chen G, Goss P, Tu D, et al.
Breast Cancer Res Treat
. 2020 Jul;
183(3):705-716.
PMID: 32715442
Purpose: To examine associations between the UGT2B17 gene deletion and exemestane metabolites, and commonly reported side effects (fatigue, hot flashes, and joint pain) among postmenopausal women participating in the MAP.3...
3.
Villarreal-Garza C, Platas A, Miaja M, Fonseca A, Mesa-Chavez F, Garcia-Garcia M, et al.
JCO Glob Oncol
. 2020 Mar;
6:395-406.
PMID: 32142405
Purpose: The pilot-phase report of the Joven & Fuerte prospective cohort broadly characterizes and assesses the needs of Mexican young women with breast cancer (YWBC). Patients And Methods: Women age...
4.
Debiasi M, Polanczyk C, Ziegelmann P, Barrios C, Cao H, Dignam J, et al.
Front Oncol
. 2018 Jun;
8:156.
PMID: 29872641
Background: Several (neo)adjuvant treatments for patients with HER2-positive breast cancer have been compared in different randomized clinical trials. Since it is not feasible to conduct adequate pairwise comparative trials of...
5.
Meggetto O, Maunsell E, Chlebowski R, Goss P, Tu D, Richardson H
J Clin Oncol
. 2017 Jan;
35(6):629-635.
PMID: 28068170
Purpose Aromatase inhibitors are established breast cancer chemoprevention interventions. However, nonadherence remains a significant challenge. We investigated the association between worsening menopause-specific quality of life, baseline participant characteristics, and early...
6.
Hernandez-Blanquisett A, Touya D, Strasser-Weippl K, Ruiz R, St Louis J, Goss P
Breast
. 2016 Aug;
29:170-7.
PMID: 27526299
The HER2 receptor as measured by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) is overexpressed in 15-20% of all breast cancers and traditionally represents adverse biology and a guarded...
7.
Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, et al.
Oncologist
. 2014 Mar;
19(4):348-9.
PMID: 24674874
Background: Endocrine therapy resistance in hormone receptor-positive (HR+) breast cancer (BC) may involve crosstalk between HRs and growth factor signaling pathways. We evaluated bosutinib, a dual Src/Abl tyrosine kinase inhibitor...
8.
Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, et al.
Oncologist
. 2014 Mar;
19(4):346-7.
PMID: 24674873
Background: Bosutinib is an oral, selective Src/Abl tyrosine kinase inhibitor with activity in breast cancer (BC). We evaluated bosutinib plus exemestane as second-line therapy in previously treated hormone receptor-positive (HR+)...
9.
LaCroix A, Powles T, Osborne C, Wolter K, Thompson J, Thompson D, et al.
J Natl Cancer Inst
. 2010 Nov;
102(22):1706-15.
PMID: 21051656
Background: Currently available selective estrogen receptor modulators reduce the risk of breast cancer, but they are not widely used. In the Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) trial, lasofoxifene...
10.
Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, et al.
Menopause
. 2010 Jun;
17(5):908-16.
PMID: 20581724
Objective: Hot flashes are a major quality-of-life issue for breast cancer survivors, interrupting sleep, reducing quality of life, and diminishing treatment adherence to adjuvant endocrine therapies. Serotonin-norepinephrine reuptake inhibitors (SNRIs)...